Parkinson'
Conditions
Interventions
prucalopride : standard dose 2 mg (1mg/tab x 2 tab)oral once daily dose or 1 mg oral once daily dose if the patients are older than 65 years or chronic kidney disease stage 4 or 5,placebo : 2 tab oral
Experimental Drug,Placebo Comparator Drug
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years old or older 2. Fulfilled the UK Parkinson’s Disease Brain Bank criteria for PD 3. motor fluctuation by 9 item wearing off questionnaire 4. No anti-PD medication adjustment within the past 3 months
Exclusion criteria
Exclusion criteria: 1. Presence of diabetes mellitus, chronic renal diseases, chronic liver disease, thyroid diseases or connective tissue disorders 2. Dementia 3. QT prolongation 4. Previous history of ventricular arrhythmia or myocardial infarction 5. Cirrhosis child pugh turcotte class C 6. Previous history of gastric surgery 7. Previous history of prolactinoma 8. Pregnant or lactating woman 9. Allergy to egg, prucalopride
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percent of daily on time Within 24 hours after taking the drug on average in 7 days patient assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| Unified Parkinson’s Disease Rating Scale(UPDRS) part III after taking drug 1 hour at day 0 and day 28 Neurologist assessment ,gastric emptying time after taking drug 1 hour at day 0 and day 28 gastric emptying scintigraphy,the Gastroparesis Cardinal Symptom Index at day 0 and day 28 patient assessment,side effect of prucalopride at day 28 patient assessment | — |
Countries
Thailand
Contacts
Public Contactporntipa apiwatnakorn
Maharaj nakorn Chiang mai hospital
Outcome results
None listed